^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AIM-001

    i
    Associations
    News

    Trials

    Company:
    EpicentRx
    Drug class:
    Immunostimulant, TGF-β1 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors (BETA-PRIME) (NCT04673942)
    Phase 2
    EpicentRx, Inc.
    Recruiting
    Last update posted :
    05/09/2024
    Initiation :
    03/29/2021
    Primary completion :
    12/01/2025
    Completion :
    03/01/2027
    TGFB1
    |
    AIM-001